Krystal Biotech

@KrystalBiotech

Krystal Biotech, Inc. is using gene therapy to develop effective and novel treatments for skin diseases.

Vrijeme pridruživanja: veljača 2018.

Medijski sadržaj

  1. 27. sij

    We broke ground on a second cGMP facility for our treatments for skin conditions. The Astra facility is intended to support potential commercial production of B-VEC, formerly KB103, as well as ongoing R&D efforts. Full details here:

  2. 26. stu 2019.

    CEO Krish S. Krishnan will be presenting a corporate update at the upcoming Piper Jaffray 31st Annual Healthcare Conference in New York on Tuesday December 3 at 9:10 a.m. ET. Webcast link for the presentation can be found here:

  3. 29. lis 2019.

    In the final data update from the Phase 1/2 trial of KB103, now B-VEC, the topical induced rapid and durable wound closure in patients with dystrophic and was safe and well-tolerated. Read the full release here:

  4. 10. lis 2019.

    The EMA Committee for Orphan Medicinal Products issued a positive opinion on our orphan designation application for KB105, our second treatment, for patients with transglutaminase-1 deficient autosomal recessive congenital ichthyosis:

  5. 9. ruj 2019.

    A new was just initiated and will study topical KB105 for treatment of transglutaminase-1 (TGM1) deficient autosomal recessive congenital (ARCI). Read more about the trial here:

  6. 3. ruj 2019.

    CEO Krish Krishnan shares his advice with on raising capital in and on how previous success in the industry paved the way for an initially self-funded company and a rapid IPO. Read the full story here:

  7. 20. kol 2019.

    KB103 study coordinator Dr. Peter Marinkovich was featured in speaking about trial results, future plans and the hope this developmental could give to all those affected by dystrophic . Read it here:

  8. 5. kol 2019.

    Krystal reports second quarter 2019 financial results including recent milestones and program updates. Full release here:

  9. 24. lip 2019.

    Data from the Phase 2 GEM2 study show that KB103 was well-tolerated and induced rapid & durable wound closure in adult & pediatric patients with dystrophic . Granted RMAT designation paves way for a planned pivotal Phase 3 before 2020.

  10. 14. lip 2019.

    We submitted an IND for a new candidate, KB105, for patients with the TGM-1 deficient autosomal recessive congenital ichthyosis (“ARCI”). Read the full release here:

  11. 29. ožu 2019.

    KB103, our clinical-stage first-in-class topical for the treatment of dystrophic , was granted PRIME eligibility by , allowing for frequent and early interactions with the EMA to accelerate development:

  12. 6. ožu 2019.

    We celebrated the opening of Ancoris, our GMP facility for all production needs for KB103, our developmental treatment for dystrophic . We were honored to be joined by :

  13. 4. ožu 2019.

    Join us in welcoming the newest member of our Board of Directors, Julian S Gangolli, whose vast experience with product launches will be invaluable as we progress our lead developmental product KB103 towards commercialization. For more details, see here:

  14. 19. pro 2018.

    We've dosed the final 4 pediatric and adult patients of 6 total in the GEM-Phase 2 with KB103, the first-ever topically-applied for this devastating . Top-line results in 1H2019. Read more here

  15. 30. lis 2018.

    .@EBPartner is the largest non-profit organization dedicated to funding research for . To date this organization has raised over $25 million to find the best treatment options for this disease. Learn more about them here:

  16. 29. lis 2018.

    We are proud to be partners with the . This organization is unique because almost all of the donations they receive go to developing research programs in the hope of finding a cure for . Check them out here:

  17. 26. lis 2018.

    Want to help raise awareness during ? Join in its social media campaign by recording a video of yourself popping a water balloon to “help make the blisters stop”

  18. 25. lis 2018.

    We are honored to have received a Partners in Progress award from for our efforts to develop potentially life-changing new treatments for everyone affected by . We are stronger when we stand together with our allies to

  19. 25. lis 2018.

    Today is the first day of ! Tonight we will be attending the 20th annual Benefit which honors key people who have had a major impact in awareness. Team DEBRA does so much to help raise awareness for :

  20. 15. lis 2018.

    Today we announced positive interim data from our first-in-human study of KB103 in patients with . The topically-applied hit primary and secondary endpoints with no safety concerns. Read here for more info:

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·